

***PLEKHS1*: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer**

GÉRALDINE PIGNOT¹, CONSTANCE LE GOUX², SOPHIE VACHER²,
ANNE SCHNITZLER², FRANÇOIS RADVANYI³, YVES ALLORY⁴,
FRANÇOIS LALLEMAND², NICOLAS BARRY DELONGCHAMPS⁵, MARC ZERBIB⁵,
BENOIT TERRIS⁶, DIANE DAMOTTE^{6,7} and IVAN BIECHE^{2,8}

¹Unit of Oncological Surgery 2, Paoli-Calmettes Institute, Marseille F-13009; ²Pharmacogenomics Unit, Genetics Department, Institut Curie; ³Molecular Oncology Team, Institut Curie, UMR 144-CNRS;

⁴Pathology Department, Institut Curie, Paris F-75005; ⁵Urology Department, Cochin Hospital, Paris Descartes University, ⁶Pathology Department, Cochin Hospital, Paris Descartes University, Paris F-75014; ⁷Cancer and Anti-tumor Immunity, INSERM U1138, Cordeliers Research Center;

⁸Inserm U1016, Cochin Institute, Paris Descartes University, Paris F-75006, France

Received February 28, 2019; Accepted June 3, 2019

DOI: 10.3892/ol.2019.10706

Abstract. Promoter mutations of pleckstrin homology domain-containing S1 (*PLEKHS1*) are frequent in several cancer types. To evaluate the DNA mutations, the mRNA expression and prognostic value of *PLEKHS1* was evaluated in bladder cancer. We investigated DNA mutations and mRNA expression of *PLEKHS1* in a first series of 154 bladder tumors [71 non-muscle-invasive bladder cancer (NMIBC) and 83 muscle-invasive bladder cancers (MIBC)] from patients who underwent transurethral bladder resection or radical cystectomy between 2001 and 2006, and 20 normal bladder samples. Results were then validated in a second series of 181 bladder tumors (91 NMIBC and 90 MIBC). All patients have signed an informed consent form. DNA mutations were analysed by high-resolution melt analysis and sanger sequencing. The mRNA expression was measured by real-time reverse-transcriptase quantitative PCR. The results of the molecular analysis were compared with survival data. *PLEKHS1* mutations occurred in 25.0 and 32.2% of NMIBC and MIBC, respectively in the first series. These results were confirmed in the second series (33.0 and 37.8% of NMIBC and MIBC, respectively). In MIBC, DNA mutations were significantly more frequent with the basal than non-basal phenotype (61.5 vs. 27.1%; $P=0.0025$). The *PLEKHS1* mRNA level was increased in 22.5 and 27.7% of NMIBC and MIBC tumors

but was not associated with DNA mutations. In NMIBC, *PLEKHS1* mRNA overexpression was significantly associated with progression to muscle-invasive disease ($P=0.0069$) and remained an independent prognostic factor on multivariate analysis ($P=0.034$). DNA mutations of *PLEKHS1* occurred in one-third of bladder tumors and was frequent in the basal MIBC phenotype. *PLEKHS1* mRNA overexpression may be an independent prognostic factor of progression-free survival in NMIBC.

Introduction

Bladder cancer is the sixth most common cause of cancer mortality and its incidence has increased markedly in recent decades (1,2) as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8 to 15% higher in more

Correspondence to: Dr Constance Le Goux, Pharmacogenomics Unit, Genetics Department, Institut Curie, 26 Rue d'Ulm, Paris F-75005, France
E-mail: constance.legoux@gmail.com

Key words: bladder cancer, DNA mutations, molecular marker, prognosis, reverse transcription-PCR

developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer). Current prognostic factors, namely TNM stage and pathological grade, insufficiently predict outcome at the individual level. The different outcome for patients with the same stage and grade calls for new prognostic molecular markers that may also serve as therapeutic targets.

Several high-throughput studies have focused on delineating genomic changes and gene expression in the various stages of bladder-cancer development and progression. Recent genomic analyses, part of The Cancer Genome Atlas, have identified several new target genes not previously described in bladder carcinogenesis (3-6).

Pleckstrin homology domain-containing S1 (*PLEKHS1*) is one of the most remarkable targets, because after telomerase reverse transcriptase (*TERT*), it is the second gene of the human genome showing frequent somatic non-coding mutations within its promoter (7). This gene, located on chromosome 10q25.3, encodes the *PLEKHS1* protein with unknown function. These mutations are single-nucleotide substitutions in the *PLEKHS1* proximal promoter (in intron 1 with a non-coding exon 1 from NM_024889.4): substitutions that effect guanine at position Chr.10: 115511590 and cytosine at position Chr.10: 115511593 from the GRCh37 (*hg19*) genomic coordinate (or c.-20+70G and c.-20+73C from NM_024889.4). These mutations are close to the translation start site of the *PLEKHS1* gene (-3,447 and -3,444 bp upstream of the translation start site) and are flanked by stretches of 10 bp on both sides that are palindromic to each other. The two *PLEKHS1* promoter mutations could be considered among the most common noncoding mutations in cancer. In bladder cancer, almost 40% of tumors could be affected by promoter mutations of this gene (8). However, data on messenger ribonucleic acid (mRNA) expression levels in bladder cancer are still lacking.

We analyzed the frequency of promoter mutations and mRNA expression of *PLEKHS1* in two large series of 335 bladder tumors: 162 non-muscle-invasive bladder cancer (NMIBC) (71 and 91, respectively) and 173 muscle-invasive bladder cancers (MIBC) (83 and 90, respectively). A retrospective review of patient outcomes allowed for performing survival analyses to highlight the putative prognostic value of this gene.

Patients and methods

Patients and samples. We analyzed samples from two series of patients with urothelial carcinoma of the bladder. The first series consisted of 154 patients who had undergone transurethral bladder resection or a radical cystectomy in our hospital between 2002 and 2007. Immediately after surgery, tumor samples from each patient were frozen in liquid nitrogen and stored at -80°C [for DNA (deoxyribonucleic acid) and RNA extraction] and fixed in formaldehyde. Specimens of normal bladder tissue from 20 patients undergoing surgery unrelated to bladder tumors (transurethral resection of the prostate, prostatic adenomectomy) were used as sources of normal bladder tissues.

Each tumor was reviewed by two pathologists (DD and MS) who were blinded to the clinical outcomes. Tumors were re-staged according to the 2009 TNM classification of bladder tumors (9) and were graded according to the WHO 2004 tumor-grading scheme (10). Standard follow-up visits followed current guidelines.

The second series was collected from 181 patients treated surgically between 1988 and 2006 at Henri Mondor Hospital, Institut Gustave Roussy (Villejuif, France) and Foch Hospital (Suresnes, France). Pure SCC and pure adenocarcinoma were excluded. Immediately after surgery, tumor samples from each patient were frozen in liquid nitrogen and stored at -80°C (for DNA and RNA extraction) and fixed in formaldehyde. For non muscle invasive cases (stage Ta or T1), TURB material was used; for muscle invasive cases, TURB or cystectomy material was used, without prior neoadjuvant chemotherapy, as previously described in Rebouissou *et al* (11).

All patients provided written informed consent. These studies received approval from an institutional review board, Centre d'Éthique Clinique de l'Hôpital Cochin, and was conducted according to the principles outlined in the Declaration of Helsinki.

DNA mutation analysis. *PLEKHS1* has two mutational spots that are well described. The assessment was performed by a screening with high-resolution melt (HRM) analysis followed by Sanger sequencing of samples with a mutated profile on HRM to validate the HRM data and determine the nomenclature of mutations found. The nucleotide sequences for the primers were for *PLEKHS1*-U (5'-CTTCCAAGGCTGGGATGATCTA-3') and *PLEKHS1*-L (5'-AAGAAAGTGCCATAACAGAAATACA-3') (polymerase chain reaction (PCR) product of 107 bp).

Real-time RT-qPCR. The theoretical basis, primers and PCR consumables, RNA extraction, complementary deoxyribonucleic acid (cDNA) synthesis, and PCR-reaction conditions were previously described in detail (12). One endogenous RNA control gene was chosen, namely *TBP* (GenBank accession no. NM_003194), which encodes the TATA box-binding protein. Because *PLEKHS1* was expressed in tumor samples but not normal bladder tissue, values were normalized so that a Ct value of 35 was set to 1. Taking into account the optimal cut-off for *PLEKHS1*, mRNA values ≥ 100 were considered overexpression.

Primers were chosen with the assistance of the Oligo 6.0 computer program (National Biosciences, Plymouth, MN). The nucleotide primer sequences were *PLEKHS1*-U (5'-AAGATGTTTAAATGCCACCCTGATG-3') and *PLEKHS1*-L (5'-CCAGTCTTTAATCTTCTCCCTGTCGT-3') (PCR product of 99 bp). Experiments were performed in duplicate for each data point.

Statistical analysis. The clinicopathologic features of NMIBC and MIBC were tested for their association with tumor recurrence and survival by Student's t-test for continuous variables or χ^2 test for qualitative variables. The distribution of mRNA levels was described with medians (range). Relationships between clinical and histological variables and mRNA levels of *PLEKHS1* were tested by the non-parametric Mann-Whitney

Table I. Clinical, pathological and survival characteristics of the 71 NMIBC of the first series.

Characteristic	Whole population, n (%)	No recurrence, n (%)	Recurrence		Muscle-invasive progression	
			n (%)	P-value ^a	n (%)	P-value ^b
Total population	71 (100.0)	25 (35.2)	36 (50.7)		10 (14.1)	
Age (years)						0.08
≥60	56 (78.9)	19 (76.0)	27 (75.0)	0.93	10 (100.0)	
<60	15 (21.1)	6 (24.0)	9 (25.0)		0 (0.0)	
Sex						
Male	63 (88.7)	22 (88.0)	32 (88.9)	0.91	9 (90.0)	0.89
Female	8 (11.3)	3 (12.0)	4 (11.1)		1 (10.0)	
Smoking status						
Non-smoker	33 (46.5)	13 (52.0)	15 (41.7)	0.43	5 (50.0)	0.81
Smoker	38 (53.5)	12 (48.0)	21 (58.3)		5 (50.0)	
History of NMIBC						
No	39 (54.9)	22 (88.0)	13 (36.1)	<0.0001	4 (40.0)	0.31
Yes	32 (45.1)	3 (12.0)	23 (63.9)		6 (60.0)	
Associated pTis						
No	69 (97.2)	25 (100.0)	36 (100.0)	0.99	8 (80.0)	0.0004
Yes	2 (2.8)	0 (0.0)	0 (0.0)		2 (20.0)	
Grade						
Low	25 (35.2)	10 (40.0)	14 (38.9)	0.93	1 (10.0)	0.07
High	46 (64.8)	15 (60.0)	22 (61.1)		9 (90.0)	
Tumor stage						
Ta	42 (59.2)	15 (60.0)	24 (66.7)	0.59	3 (30.0)	0.043
T1	29 (40.8)	10 (40.0)	12 (33.3)		7 (70.0)	

^aχ² test (recurrence vs no recurrence); ^bχ² test (muscle-invasive progression vs. others). NMIBC, non-muscle-invasive bladder cancer.

U test and Kruskal-Wallis H-test. Overall survival (OS) was calculated from the date of surgery until death or the last follow-up. Recurrence-free survival (RFS) was defined as the time from the date of surgery to the first local relapse or first metastasis. For NMIBC, progression-free survival (PFS) was defined as the time from the date of surgery to progression to muscle-invasive disease. Survival curves were derived from Kaplan-Meier estimates. The log-rank test was used to compare survival between subgroups. The prognostic impact of mRNA levels, adjusted for the other prognostic factors, was assessed by Cox proportional-hazards regression analysis, estimating hazard ratios and 95% confidence intervals. The variables significant in univariate analysis (P<0.10) were included in multivariate analysis. Differences were considered significant at P<0.05.

Results

Clinicopathologic characteristics of the cohorts. Complete clinical, histological and survival data were obtained from medical records for these 154 patients [129 men and 25 women; median age 70 years (range, 31-91)]. Pathological staging showed NMIBC in 71 patients (25 low-grade pTa,

17 high-grade pTa, 29 high-grade pT1) and high-grade MIBC in 83 patients. For NMIBC, the median follow-up was 57.4 months (range, 1-158 months; mean follow-up, 61 months). For MIBC, the median follow-up was 12.5 months (range, 1-152 months; mean follow-up, 29 months). In the MIBC cohort, 12 patients (14.5%) received neoadjuvant chemotherapy before cystectomy and 25 (30.1%) received adjuvant chemotherapy taking into account pathological characteristics of the tumor and renal function. Clinical, histological and survival characteristics for the first series are presented in Tables I and II.

The second series consisted of an independent cohort of 181 patients with bladder cancer [150 men and 31 women; median age 67 years (range, 30-95)]. Pathological staging showed NMIBC in 91 patients (33 low-grade pTa, 17 high-grade pTa, 41 high-grade pT1) and high-grade MIBC in 90 patients. In this second cohort, molecular subgroups (basal phenotype, called MC7, vs non-basal phenotype) were previously determined by using the CIT (Carte d'Identité des Tumeurs) classification (11) we identified an MIBC subgroup accounting for 23.5% of MIBC, associated with shorter survival and displaying a basal-like phenotype, as shown by the expression of epithelial basal cell

Table II. Clinical, pathological and survival characteristics of the 83 muscle-invasive bladder cancer of the first series.

Characteristic	Whole population, n (%)	Disease-free survival		Overall survival	
		Number of events (%) ^a	P-value ^c	Number of events (%) ^b	P-value ^c
Total population	83 (100.0)	48 (57.8)		46 (55.4)	
Age (years)					
≥60	61 (73.5)	40 (65.5)	0.017	39 (63.9)	0.009
<60	22 (26.5)	8 (36.4)		7 (31.8)	
Sex					
Male	66 (79.5)	36 (54.5)	0.23	38 (57.6)	0.44
Female	17 (20.5)	12 (70.6)		8 (47.1)	
Smoking status					
Non-smoker	34 (41.0)	18 (52.9)	0.45	12 (35.3)	0.002
Smoker	49 (59.0)	30 (61.2)		34 (69.4)	
History of NMIBC					
No	59 (71.1)	30 (50.8)	0.043	31 (52.5)	0.41
Yes	24 (28.9)	18 (75.0)		15 (62.5)	
Associated pTis					
No	73 (88.0)	43 (58.9)	0.59	40 (54.8)	0.76
Yes	10 (12.0)	5 (50.0)		6 (60.0)	
Tumor stage					
T2	34 (41.0)	17 (50.0)	0.10	13 (38.2)	0.009
≥T3	49 (59.0)	31 (63.3)		33 (67.3)	
Lymph node status					
N-	58 (69.9)	27 (46.6)	0.002	25 (43.1)	0.0006
N+	25 (30.1)	21 (84.0)		21 (84.0)	

^aFirst recurrence (local or metastatic); ^bDeath; ^c χ^2 test. NMIBC, non-muscle-invasive bladder cancer.

markers. Basal-like tumors presented an activation of the epidermal growth factor receptor (EGFR). None patient of the second cohort received neoadjuvant chemotherapy. As in the first cohort, patients received adjuvant chemotherapy taking into account pathological characteristics of the tumor if they were eligible. Clinical and histological variables did not differ between the two series, except for history of NMIBC (Table III).

DNA mutations of *PLEKHS1*. DNA mutation analysis involved 103 available tumor DNA samples (44 NMIBC and 59 MIBC) from the first series and 18 normal bladder samples, then the 181 tumor samples (91 NMIBC and 90 MIBC) from the second series.

In the first series, 11/44 NMIBC (25.0%) and 19/59 MIBC (32.2%) samples had a promoter-mutated profile (Table IV). The *PLEKHS1* promoter exhibited recurrent mutations at two genomic positions: c.-20+70 (G>A and G>C) and c.-20+73 (C>A, C>T and C>G). NMIBC and MIBC samples did not differ by type of mutation (P=0.43).

In the second series, 30/91 NMIBC (33.0%) and 34/90 MIBC (37.8%) samples had a promoter-mutated profile (Table IV). The DNA-mutated profile was not significantly associated with clinical parameters for patients with NMIBC

(Table V) or MIBC (Table VI). Regarding molecular subgroups in MIBC, a DNA-mutated profile was significantly more frequent with the basal phenotype (MC7) than the non-basal phenotype (61.5 vs. 27.1%, P=0.0025). *PLEKHS1* DNA mutation was not associated with prognosis, in terms of recurrence or progression with NMIBC and in terms of RFS or OS with MIBC (data not shown).

mRNA expression of *PLEKHS1*. The mRNA expression of *PLEKHS1* was assessed in the first series (n=154). The median mRNA *PLEKHS1* level was 19.7 [range, 0.0-972.6] with NMIBC and 25.7 [0.0-2288.1] with MIBC, vs. 0.0 [0.0-21.4] in normal bladder samples. *PLEKHS1* was overexpressed in NMIBC and MIBC versus normal bladder tissue (P=0.00031 and P=0.000025), with no difference in level between NMIBC and MIBC (P=0.51). Overall, 22.5 and 27.7% of NMIBC and MIBC tumors showed *PLEKHS1* overexpression (vs. 0% in normal bladder samples, P<0.01). *PLEKHS1* mRNA level was not associated with DNA mutations in NMIBC (P=0.39) or MIBC (P=0.84).

Prognostic value of *PLEKHS1* mRNA overexpression. *PLEKHS1* mRNA overexpression was not significantly associated with clinical variables in NMIBC (Table VII) or MIBC

Table III. Clinical and pathological characteristics of NMIBC and MIBC the two series.

A, NMIBC				
Characteristic	Whole population, n (%)	First series, n (%)	Second series, n (%)	P-value ^h
Total population	162 (100.0)	71 (100.0)	91 (100.0)	
Age (years) ^a				
≥60	108 (72.0)	56 (78.9)	52 (65.8)	0.08
<60	42 (28.0)	15 (21.1)	27 (34.2)	
Sex				
Male	138 (85.2)	63 (88.7)	75 (82.4)	0.26
Female	24 (14.8)	8 (11.3)	16 (17.6)	
History of NMIBC ^b				
No	108 (71.5)	39 (54.9)	69 (86.3)	<0.0001
Yes	43 (28.5)	32 (45.1)	11 (13.7)	
Associated pTis ^c				
No	134 (93.7)	69 (97.2)	65 (90.3)	0.09
Yes	9 (6.3)	2 (2.8)	7 (9.7)	
Grade				
Low	58 (35.8)	25 (35.2)	33 (36.3)	0.89
High	104 (64.2)	46 (64.8)	58 (63.7)	
Tumor stage				
Ta	92 (56.8)	42 (59.2)	50 (54.9)	0.59
T1	70 (43.2)	29 (40.8)	41 (45.1)	
B, MIBC				
Characteristic	Whole population, n (%)	First series, n (%)	Second series, n (%)	P-value ^h
Total population	173 (100.0)	83 (100.0)	90 (100.0)	
Age (years) ^d				
≥60	124 (73.8)	61 (73.5)	63 (74.1)	0.93
<60	44 (26.6)	22 (26.5)	22 (25.9)	
Sex				
Male	141 (81.5)	66 (79.5)	75 (83.3)	0.52
Female	32 (18.5)	17 (20.5)	15 (16.7)	
History of NMIBC ^e				
No	135 (84.4)	73 (88.0)	62 (80.5)	0.20
Yes	25 (15.6)	10 (12.0)	15 (19.5)	
Associated pTis ^f				
No	135 (84.4)	73 (88.0)	62 (80.5)	0.20
Yes	25 (15.6)	10 (12.0)	15 (19.5)	
Tumor stage				
T2	66 (38.2)	34 (41.0)	32 (35.6)	0.46
≥T3	107 (61.8)	49 (59.0)	58 (64.4)	
Lymph node status ^g				
N ⁻	93 (63.7)	58 (69.9)	35 (55.6)	0.07
N ⁺	53 (36.3)	25 (30.1)	28 (44.4)	

^aData available for 79 patients; ^bdata available for 80 patients; ^cdata available for 72 patients, in the second series; ^ddata available for 85 patients; ^edata available for 83 patients; ^fdata available for 77 patients; ^gdata available for 63 patients, in the second series. ^h χ^2 test. NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer.

(Table VIII). With NMIBC, *PLEKHS1* overexpression was associated with worse PFS on univariate analysis (P=0.0069) (Fig. 1). Five- and 10-year PFS rates were 72.4 and 38.8%

with *PLEKHS1* overexpression versus 88.9 and 88.7% without *PLEKHS1* overexpression. Other clinical variables affecting PFS on univariate analysis with P<0.10 on log-rank test

Table IV. Frequency of mutations in the *PLEKHS1* promoter in the two series.

<i>PLEKHS1</i> profile	First series (n=103)			Second series (n=181)		
	Mutated n (%)	Not mutated n (%)	P-value ^a	Mutated n (%)	Not mutated n (%)	P-value ^a
All tumors	30 (29.1)	73 (70.9)	0.43	64 (35.4)	117 (64.4)	0.50
NMIBC	11 (25.0)	33 (75.0)		30 (33.0)	61 (67.0)	
MIBC	19 (32.2)	40 (67.8)		34 (37.8)	56 (62.2)	

^a χ^2 test. *PLEKHS1*, pleckstrin homology domain-containing S1; NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer.

Table V. Association of clinicopathological variables and *PLEKHS1* DNA mutated profile with NMIBC from the second series.

Characteristic	Total population, n (%)	<i>PLEKHS1</i> mutated, n (%)	Not mutated, n (%)	P-value ^a
Total	91 (100.0)	30 (33.0)	61 (67.0)	
Age (years) ^b				0.95
≥60	52 (65.8)	17 (32.7)	35 (67.3)	
<60	27 (34.2)	9 (33.3)	18 (66.7)	
Sex				0.74
Male	75 (82.4)	26 (35.1)	48 (64.9)	
Female	16 (17.6)	4 (26.7)	11 (73.3)	
History of NMIBC ^c				0.36
No	69 (86.3)	26 (37.7)	43 (62.3)	
Yes	11 (13.7)	2 (18.2)	9 (81.8)	
Associated pTis ^d				0.37
No	65 (90.3)	21 (32.3)	44 (67.7)	
Yes	7 (9.7)	4 (57.1)	3 (42.9)	
Grade				0.098
Low	33 (36.3)	7 (21.2)	26 (78.8)	
High	58 (63.7)	21 (38.2)	34 (61.8)	
Tumor stage				0.27
Ta	50 (54.9)	14 (28.0)	36 (72.0)	
T1	41 (45.1)	16 (39.0)	25 (61.0)	
Phenotype ^e				0.76
Basal	1 (1.3)	0 (0.0)	1 (100.0)	
Non-basal	78 (98.7)	26 (33.3)	52 (66.7)	

^a χ^2 test. ^bData available for 79 patients; ^cdata available for 80 patients; ^ddata available for 72 patients; ^edata available for 79 patients. *PLEKHS1*, pleckstrin homology domain-containing S1; NMIBC, non-muscle-invasive bladder cancer.

included T stage and grade and were retained for multivariate analysis. On multivariate analysis, *PLEKHS1* overexpression remained an independent prognostic factor of PFS (P=0.034) (Table IX).

Overall, 21/28 patients (75%) who received Bacillus Calmette-Guerin (BCG) therapy showed recurrent NMIBC or progression to an invasive tumor during follow-up, including 15 (53.6%) within the first 2 years. The median *PLEKHS1* mRNA level was higher but not significantly with BCG-refractory tumor or early recurrence (<24 months)

than for BCG responders (no recurrence or >24 months): 40.8 [range, 0.0-375.5] vs. 15.2 [0.6-381.6] (P=0.80).

With MIBC, *PLEKHS1* overexpression was not associated with RFS or OS (P=0.33 and P=0.057, respectively).

Discussion

Mutations of *PLEKHS1* are non-coding and are located in the gene promoter and therefore cannot be detected by whole-exome analyses. This is also the case for non-coding

Table VI. Association of clinicopathological variables and *PLEKHS1* DNA mutated profile with MIBC from the second series.

Characteristic	Total population, n (%)	<i>PLEKHS1</i> mutated, n (%)	Not mutated, n (%)	P-value ^a
Total	90 (100)	34 (64.8)	56 (35.2)	
Age ^b				
≥60	63 (74.1)	26 (41.3)	37 (58.7)	0.24
>60	22 (25.9)	6 (27.3)	16 (72.7)	
Sex				
Male	75 (83.3)	29 (38.7)	46 (61.3)	0.70
Female	15 (16.7)	5 (33.3)	10 (66.7)	
History of NMIBC ^c				
No	71 (85.5)	26 (36.6)	45 (63.4)	0.38
Yes	12 (14.5)	6 (50.0)	6 (50.0)	
Associated pTis ^d				
No	62 (80.5)	25 (40.3)	37 (59.7)	0.62
Yes	15 (19.5)	5 (33.3)	10 (66.7)	
Tumor stage				
T2	32 (35.6)	16 (50.0)	16 (50.0)	0.076
≥T3	58 (64.4)	18 (31.0)	40 (69.0)	
Lymph node status ^e				
N-	35 (55.6)	14 (40.0)	21 (60.0)	0.52
N+	28 (44.4)	9 (32.1)	19 (67.9)	
Phenotype ^f				
Basal	26 (30.6)	16 (61.5)	10 (38.5)	0.0025
Non-basal	59 (69.4)	16 (27.1)	43 (72.9)	

^a χ^2 test. ^bData available for 85 patients; ^cdata available for 83 patients; ^ddata available for 77 patients; ^edata available for 63 patients; ^fdata available for 85 patients. *PLEKHS1*, pleckstrin homology domain-containing S1; MIBC, muscle-invasive bladder cancer.




Figure 1. Progression-free survival with non-muscle-invasive bladder cancer by *PLEKHS1* mRNA expression. *PLEKHS1*, pleckstrin homology domain-containing S1.

mutations located on the upstream regulatory sequences for genes such as *TERT*, WD repeat domain 74 (*WDR74*) and succinate dehydrogenase complex subunit D (*SDHD*) (8). Point mutations in the *TERT* promoter are the best known and occur in a subset of tumors with clinical interest. In bladder urothelial carcinomas, almost two thirds of tumors show somatic test mutations (13).

To our knowledge, this is the first study to assess *PLEKHS1* DNA mutations and mRNA expression in bladder cancer. This assessment is of outmost importance because the association of gene expression and the prognostic impact of promoter mutations in the cancer remain unknown. Whole-genome sequencing of non-coding somatic mutations, rather than these exome studies, might provide answers to these deliberations.

Table VII. Association of clinicopathological variables and *PLEKHS1* mRNA level with NMIBC from the first series.

Characteristic	Total population, n (%)	<i>PLEKHS1</i> mRNA no overexpression, n (%)	<i>PLEKHS1</i> mRNA overexpression, n (%)	P-value ^a
Total	71 (100)	55 (77.5)	16 (22.5)	
Age				
≥60	56 (78.9)	43 (76.8)	13 (23.2)	0.79
<60	15 (21.1)	12 (80.0)	3 (20.0)	
Sex				
Male	63 (88.7)	48 (76.2)	15 (23.8)	0.79
Female	8 (11.3)	7 (87.5)	1 (12.5)	
Smoking status				
Non-smoker	33 (46.5)	25 (75.8)	8 (24.2)	0.75
Smoker	38 (53.5)	30 (78.9)	8 (21.1)	
History of NMIBC				
No	39 (54.9)	31 (79.5)	8 (20.5)	0.65
Yes	32 (45.1)	24 (75.0)	8 (25.0)	
Associated pTis				
No	69 (97.2)	54 (78.3)	15 (21.7)	0.35
Yes	2 (2.8)	1 (50.0)	1 (50.0)	
Grade				
Low	25 (35.2)	21 (84.0)	4 (16.0)	0.33
High	46 (64.8)	34 (73.9)	12 (26.1)	
Tumor stage				
pTa	42 (59.2)	35 (83.3)	7 (16.7)	0.15
pT1	29 (40.8)	20 (69.0)	9 (31.0)	

^a χ^2 test. *PLEKHS1*, pleckstrin homology domain-containing S1; NMIBC, non-muscle-invasive bladder cancer.

We investigated DNA mutations and mRNA expression in a large series of 154 bladder cancer cases. The results of DNA analysis were then validated in an independent second series (n=181). In these two series, tumors were half non-muscle invasive and half muscle invasive. Characteristics of both populations are consistent with urothelial carcinoma presentation. Moreover, we observed the classical prognostic factors (TNM stage and grade).

We showed a high frequency of promoter DNA mutations for *PLEKHS1*, detected in about one-third of bladder tumors (NMIBC and MIBC). Our results are consistent with the princeps study of Weinhold *et al* describing *PLEKHS1* DNA mutations in 8/20 samples (40%) of bladder cancer (8). This high rate of DNA mutations supports the concept of an essential involvement of this gene in bladder carcinogenesis, possibly similar to human *TERT*. It is also of interest as a biomarker to detect circulating tumor DNA that can be used for a variety of clinical and research purposes for bladder cancer.

In our study, *PLEKHS1* mutations were particularly frequent with the basal MIBC phenotype, which is known to have poor prognosis but is associated with improved survival after neoadjuvant chemotherapy (14). Further research is needed to assess the role of *PLEKHS1* in the chemosensitivity of MIBC.

PLEKHS1 mRNA was overexpressed in approximatively one-quarter of bladder tumors, regardless of stage and grade.

As well, the expression was particularly high in some tumor samples, but normal bladder tissue showed very low levels.

Although the rates of mutations appear to be almost the same as the proportion of mRNA overexpression, we did not find an association between DNA alterations and mRNA expression. This is an unexpected result suggesting that mutations in the *PLEKHS1* promoter probably do not affect transcription and are not responsible for the increased mRNA expression in our bladder tumor series. Our results disagree with those of Weinhold *et al.*, who showed *PLEKHS1* mutations inversely correlated with mRNA expression level in a small series of 20 bladder tumors (8). In contrast, somatic mutations in the *TERT* promoter increased the expression of telomerase (13).

In NMIBC, *PLEKHS1* overexpression was associated with poor prognosis and increased risk of progression to muscle-invasive disease. The overexpression remained an independent prognostic factor on multivariate analysis, which is quite remarkable. Indeed, except for TNM stage and pathological grade, we have no molecular markers to distinguish tumors that would be able to progress in muscle-invasive disease during follow-up. This is especially crucial for pT1 high-grade tumors, which have been shown to progress in 30 to 50% of cases during the first 5 years. Early identification of patients at risk of disease progression

Table VIII. Association of clinicopathological variables and *PLEKHS1* mRNA level with MIBC from the first series.

Characteristic	Total population, n (%)	<i>PLEKHS1</i> mRNA no overexpression, n (%)	<i>PLEKHS1</i> mRNA overexpression, n (%)	P-value ^a
Total	83 (100)	60 (72.3)	23 (27.7)	
Age				
≥60	61 (73.5)	44 (72.1)	17 (27.9)	0.96
<60	22 (26.5)	16 (72.7)	6 (27.3)	
Sex				
Male	66 (79.5)	45 (68.2)	21 (31.8)	0.10
Female	17 (20.5)	15 (88.2)	2 (11.8)	
Smoking status				
Non-smoker	34 (41.0)	23 (67.6)	11 (32.4)	0.43
Smoker	49 (59.0)	37 (75.5)	12 (24.5)	
History of NMIBC				
No	59 (71.1)	39 (66.1)	20 (33.9)	0.05
Yes	24 (28.9)	21 (87.5)	3 (12.5)	
Associated pTis				
No	73 (88.0)	52 (71.2)	21 (28.7)	0.56
Yes	10 (12.0)	8 (80.0)	2 (20.0)	
Grade				
Low	34 (41.0)	25 (73.5)	9 (26.5)	0.83
High	49 (59.0)	35 (71.4)	14 (28.6)	
Tumor stage				
pTa	58 (69.9)	39 (68.4)	19 (32.8)	0.12
pT1	25 (30.1)	21 (84.0)	4 (16.0)	

^a χ^2 test. *PLEKHS1*, pleckstrin homology domain-containing S1; NMIBC, non-muscle-invasive bladder cancer.

Table IX. Cox proportional-hazards regression analysis of factors affecting progression-free survival with non-muscle-invasive bladder cancer.

Prognostic factor	Progression-free survival		
	HR	95% CI	P-value
T stage	3.92	(0.79-19.36)	0.093
Grade	2.19	(0.20-24.58)	0.52
<i>PLEKHS1</i> overexpression	4.01	(1.11-14.50)	0.034

PLEKHS1, pleckstrin homology domain-containing S1; HR, hazard ratio.

may lead to more aggressive therapeutic strategies, such as early cystectomy. One of the main issues is the potential response of these tumors to BCG therapy. In our series, even though *PLEKHS1* mRNA expression was three times higher with early recurrent or refractory tumor than other tumors, *PLEKHS1* was not a significant predictive factor of response to BCG therapy. However, the small number of patients who received BCG may explain the lack of statistical power in our study.

One limitation of our study is that a longer follow-up or a larger cohort of patients may be needed to show significance, especially for pT1 tumors and response to BCG. To confirm these data, prospective clinical studies associated with a molecular evaluation of tumors are needed. We tried to assess protein expression by western blot analysis and immunohistochemistry, but the two primary anti-*PLEKHS1* antibodies used (i.e., HPA037583, Sigma and H00079949-T01, Abnova) showed no specific protein bands on western blot analysis or on immunostaining (data not shown), which suggests no qualitative antibody available for *PLEKHS1*. Functional analyses should probably be done in parallel to investigate the role of *PLEKHS1* in carcinogenesis. Recently, Grossmann et al. identified an interaction between PIK3R3 (p55c regulatory subunit of PI3 kinase) and *PLEKHS1* (15), but the significance of this protein interaction remains uncertain. In our series, even if *PLEKHS1* mutations were significantly more frequent with the basal than non-basal MIBC phenotype, we did not identify any other associated gene or pathway alterations. Therefore, despite its prognostic value, *PLEKHS1* cannot be considered a therapeutic target at this time.

Our results support the involvement of *PLEKHS1* in bladder carcinogenesis. DNA mutations were observed in almost one-third of bladder cancers and approximately one quarter of NMIBC and MIBC tumors showed mRNA

overexpression. In MIBC, *PLEKHS1* mutations seem frequent with the basal phenotype. In NMIBC, *PLEKHS1* overexpression may be an independent prognostic factor of progression to muscle-invasive disease. Our study has many biases since it is a retrospective clinical study, small cohort and can only be considered as a preliminary study. The clinical interest remains to be demonstrated by a prospective study centered on high grade NMIBC. Further studies are needed to dissect the mechanisms of action and the specific role of *PLEKHS1* in bladder carcinogenesis and to develop therapeutic inhibitors.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

GP and CLG contributed to the acquisition and interpretation of data, and manuscript writing. SV, AS and FL contributed to the acquisition of data. FR, YA, NBD, MZ and BT acquired the data. DD contributed to acquisition and interpretation of data. IB contributed to the conception and design of the study, and interpretation of data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the local ethics and research committee of Mondor and Foch Hospitals, Centre d'Éthique Clinique de l'Hôpital Cochin (descriptive retrospective study). All patients provided written informed consent.

Patient consent for publication

All patients provided informed consent.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. *CA Cancer J Clin* 65: 87-108, 2015.
2. Lebreton T, Hervé JM, Yonneau L, Barré P, Lugagne PM, Buteau M, Molinié V and Botto H: Study of survival after cystectomy for bladder cancer. Report of 504 cases. *Prog Urol* 10: 553-560, 2000 (In French).
3. Salvi S, Calistri D, Gurioli G, Carretta E, Serra L, Gunelli R, Zoli W and Casadio V: Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer. *Int J Mol Sci* 15: 12458-12468, 2014.
4. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature* 507: 315-322, 2014.
5. Williams SV, Hurst CD and Knowles MA: Oncogenic FGFR3 gene fusions in bladder cancer. *Hum Mol Genet* 22: 795-803, 2013.
6. Massari F, Bria E, Ciccarese C, Munari E, Modena A, Zamboni V, Sperduti I, Artibani W, Cheng L, Martignoni G, *et al*: Prognostic value of beta-tubulin-3 and c-Myc in muscle invasive urothelial carcinoma of the bladder. *PLoS One* 10: e0127908, 2015.
7. Pignot G, le Goux C and Bieche I: Recent advances in bladder urothelial carcinogenesis. *Bull Cancer* 102: 1020-1035, 2015 (In French).
8. Weinhold N, Jacobsen A, Schultz N, Sander C and Lee W: Genome-wide analysis of noncoding regulatory mutations in cancer. *Nat Genet* 46: 1160-1165, 2014.
9. Sobin L, Gospodarowicz M and Wittekind C (eds.): *TNM Classification of Malignant Tumors*. John Wiley and Sons, Hoboken, NJ, USA, pp 262-265, 2009.
10. Molinié V: Classification of bladder tumors in 2006. In: *Prog Urol FMC*, pp16: 7-10, 2006.
11. Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Héroult A, Kamoun A, Caillaud A, Letouze E, *et al*: EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. *Sci Transl Med* 6: 244ra91, 2014.
12. Pignot G, Bieche I, Vacher S, Güet C, Vieillefond A, Debré B, Lidereau R and Amsellem-Ouazana D: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: Identification of VEGFA as a major independent prognostic marker. *Eur Urol* 56: 678-688, 2009.
13. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovannella BC, *et al*: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc Natl Acad Sci USA* 110: 6021-6026, 2013.
14. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, *et al*: A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. *Eur Urol* 69: 855-862, 2016.
15. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D and Crawford ED: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 349: 859-866, 2003.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.